Should you buy United Therapeutics (UTHR)?
Updated
United Therapeutics generates 41% net margins and ranks best-in-class on margins among specialty pharmaceutical peers, but severe product concentration where Tyvaso DPI and Nebulized Tyvaso together account for 59% of revenue, combined with 3 earnings misses in 4 quarters, makes the current risk profile unfavorable for new positions.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
United Therapeutics generates 41% net margins and scores 10 out of 10 on both gross and operating margin dimensions, placing it among the most profitable drug manufacturers in its specialty pharmaceutical peer group. Quality breakdown | Net margins should remain above 35% over the next 12 months as the pulmonary arterial hypertension franchise continues to generate premium pricing. | →Stable |
| CounterFree cash flow is only 44% of net income, significantly below what 41% margins would imply, suggesting large capital expenditure requirements or one-time items are consuming cash that the income statement shows as profit. | ||
Tyvaso DPI and Nebulized Tyvaso together represent approximately 59% of total revenue, and Accredo and CVS Specialty are the primary distribution customers, creating significant revenue dependency on a small number of products and channels. Bear case | Tyvaso revenue share should decline below 50% over the next 12 months as the pipeline diversifies, reducing single-product dependency. | →Stable |
| CounterHigh product concentration around a market-leading rare disease therapy is a known risk that is partly offset by the difficulty competitors face in gaining FDA approval for competing pulmonary arterial hypertension products. | ||
United Therapeutics missed earnings estimates in 3 of the last 4 quarters, including a 15% miss in the most recent quarter, indicating that analyst models have been too optimistic about near-term revenue or cost trends. Earnings | The company should beat consensus estimates in at least 2 of the next 4 quarters as estimates are reset to realistic levels. | →Stable |
| CounterThe single beat quarter showed a 14% positive surprise, suggesting the business can outperform when Tyvaso demand exceeds expectations, and the overall average surprise of -2.7% is not catastrophically negative. | ||
United Therapeutics generates 41% net margins and scores 10 out of 10 on both gross and operating margin dimensions, placing it among the most profitable drug manufacturers in its specialty pharmaceutical peer group.
→Stable- Expectation
- Net margins should remain above 35% over the next 12 months as the pulmonary arterial hypertension franchise continues to generate premium pricing.
CounterFree cash flow is only 44% of net income, significantly below what 41% margins would imply, suggesting large capital expenditure requirements or one-time items are consuming cash that the income statement shows as profit.
Tyvaso DPI and Nebulized Tyvaso together represent approximately 59% of total revenue, and Accredo and CVS Specialty are the primary distribution customers, creating significant revenue dependency on a small number of products and channels.
→Stable- Expectation
- Tyvaso revenue share should decline below 50% over the next 12 months as the pipeline diversifies, reducing single-product dependency.
CounterHigh product concentration around a market-leading rare disease therapy is a known risk that is partly offset by the difficulty competitors face in gaining FDA approval for competing pulmonary arterial hypertension products.
United Therapeutics missed earnings estimates in 3 of the last 4 quarters, including a 15% miss in the most recent quarter, indicating that analyst models have been too optimistic about near-term revenue or cost trends.
→Stable- Expectation
- The company should beat consensus estimates in at least 2 of the next 4 quarters as estimates are reset to realistic levels.
CounterThe single beat quarter showed a 14% positive surprise, suggesting the business can outperform when Tyvaso demand exceeds expectations, and the overall average surprise of -2.7% is not catastrophically negative.
▸ Show 1 more pillar▾ Show fewer
Analysts set a consensus price target implying 21% upside from the current $549.57, and the stock is pulling back from overbought levels with an RSI of 32, which could represent a re-entry opportunity if the fundamental story stabilizes.
→Stable- Expectation
- The price should recover above $578 within 12 months, approaching the analyst consensus target, as earnings trajectory stabilizes.
CounterWith 4 highly concentrated risk flags from the 10-K risk factor analysis and declining revenue at -2% year-over-year, the analyst target may be too optimistic if the Tyvaso franchise faces any reimbursement or competitive pressure.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1United Therapeutics generates 41% net margins and scores 10 out of 10 on both gross and operating margin dimensions, placing it among the most profitable drug manufacturers in its specialty pharmaceutical peer group.
Trip ifNet margin falls below 30% in any of the next 4 reported quarters.
- P2Tyvaso DPI and Nebulized Tyvaso together represent approximately 59% of total revenue, and Accredo and CVS Specialty are the primary distribution customers, creating significant revenue dependency on a small number of products and channels.
Trip ifTyvaso product revenue concentration rises above 65% in any reported period.
- P3United Therapeutics missed earnings estimates in 3 of the last 4 quarters, including a 15% miss in the most recent quarter, indicating that analyst models have been too optimistic about near-term revenue or cost trends.
Trip ifEPS surprise falls below -10% in at least 2 of the next 4 quarters.
- P4Analysts set a consensus price target implying 21% upside from the current $549.57, and the stock is pulling back from overbought levels with an RSI of 32, which could represent a re-entry opportunity if the fundamental story stabilizes.
Trip ifPrice drops below $524, more than 4.5% below the current $549.57.
How the engine reached this verdict
TrendMatrix's engine output for United Therapeutics Corporation (UTHR) is SELL_IF_HOLDING with medium conviction, score 4.9/10 at $554.23. The F-path SELL output reflects an overall score of 4.9 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 0.88 is supplementary context, not the trigger.
The dominant failed gate is reward-to-risk at 0.9 vs threshold 1.5. SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.5>=5.5.
On the bull side: High-quality business. On the bear side: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Customer: Accredo and CVS Specialty; Thin upside margin: 4.4%. Active engine warnings: V9 Gate Failed: ASYMMETRY:0.9<1.5@spot.
The engine's exit framework anchors to a tactical sell band near $554.23, with structural invalidation at $530.30. The asymmetric R:R against a reversal hypothesis is 1.00 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates UTHR — 10-dimension breakdown →
Bull case
- ▸High-quality business
Bear case
- ▸Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%)
- ▸Concentration risk — Customer: Accredo and CVS Specialty
- ▸Thin upside margin: 4.4%